DOCSLIB.ORG

Human Transforming Growth Factor Α (TGF-Α)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Human Transforming Growth Factor Α (TGF-Α) 787 STOMACH Gut: first published as 10.1136/gut.51.6.787 on 1 December 2002. Downloaded from Human transforming growth factor α (TGF-α) is digested to a smaller (1–43), less biologically active, form in acidic gastric juice T Marchbank, R Boulton, H Hansen, R J Playford ............................................................................................................................. Gut 2002;51:787–792 Background: Transforming growth factor α (TGF-α) is a 50 amino acid peptide with potent prolifera- tive and cytoprotective activity present in gastric mucosa and juice. Aims: To determine the forms and biological activity of natural and recombinant TGF-α following incu- bation with acid pepsin. Patients: Human gastric juice was obtained under basal conditions from patients taking acid suppres- sants and from volunteers undergoing intragastric neutralisation. See end of article for Methods: Samples were analysed using mass spectroscopy and/or high pressure liquid chromatogra- authors’ affiliations phy with radioimmunoassay. Biological activity was determined using thymidine incorporation into rat ....................... hepatocytes and an indomethacin/restraint induced gastric damage rat model. α α Correspondence to: Results: TGF- 1–50 is cleaved to TGF- 1–43 by acid pepsin and this is the predominant form in normal Professor R J Playford, gastric juice. However, intragastric neutralisation or taking acid suppressants caused the predominant Gastroenterology Section, α α 3 form to be TGF- 1–50.TGF- 1–43 had only half of the ability to maximally stimulate [ H]thymidine incorpo- Imperial College School of α ration into primary rat hepatocytes (28 177 (1130) DPM/well for 2.16 nM TGF- 1–43 v 63 184 (3536) Medicine, Hammersmith α Hospital Campus, Du Cane DPM/well for TGF- 1–50; p<0.001). A similar reduced potency was seen when used in an indomethacin α Rd, London W12 0NN, induced rat gastric damage model (0.18 µmol/kg/h of TGF- 1–43 reduced ulcer area by 19% whereas UK; [email protected] α TGF- 1–50 reduced area by 62%; p<0.001). Conclusions: α α Accepted for publication TGF- 1–50 is cleaved to the TGF- 1–43 form by acid pepsin, causing 2–5-fold loss of bio- 30 April 2002 logical activity. Such changes may have relevance to the actions of acid suppressants and the import- ....................... ance of this peptide in both normal and abnormal growth. http://gut.bmj.com/ ransforming growth factor α (TGF-α) is a 50 amino acid Methods of analyses of samples to determine the forms peptide present in gastric juice and throughout the of TGF-α Tgastrointestinal tract.1 It is a potent stimulant of Preparation of gastric juice samples prior to high pressure proliferation of several gastrointestinal cell lines in vitro2–5 and liquid chromatography (HPLC) in the rat intestine when given systemically.6 In addition, Samples of gastric juice which were to have HPLC performed TGF-α protects against injury in a variety of gastric damaging were first concentrated using octadecylsilane (C18) cartridge on September 23, 2021 by guest. Protected copyright. 10 models such as those induced by ethanol or stress,78 and chromatography, as described by Elson and colleagues. Eluates were then dried on a centrifugal evaporator (Savant; human gastric juice concentrations of TGF-α increase in Farmingdale, New York, USA) and resuspended in 0.1% response to administration of noxious agents such as trifluoroacetic acid (TFA) prior to injection into the HPLC loop. indomethacin.9 Taken together, these studies suggest TGF-α plays a role in growth, differentiation, and maintenance of Reverse phase HPLC mucosal integrity of the bowel. Studies involving reverse phase HPLC used a Hewlett Packard As TGF-α is present in human gastric juice, it is constantly 1100 (Stockport, UK) consisting of a quaternary pump deliv- bathed in acid and pepsin. There has been virtually no work ery system, Rheodyne-7725 sample injector, anda1mlinjec- however examining whether it is adversely affected by being tion loop. The column used was an analytical “Jupiter” C5, 300 present in such a harsh environment. We therefore examined A, 5 µm (4.6×150 mm) column (Phenomenex UK Ltd). After the effect of acid and pepsin on the form and biological activ- application of the sample, the column was eluted isocratically ity of TGF-α in vitro and in vivo and determined the forms of (15% acetonitrile (AcN), 0.1% TFA) for 10 minutes before a TGF-α present in gastric juice obtained from subjects under gradient from 15–40% AcN, 0.1% TFA was run over 30 varying acidic conditions. minutes. Samples were collected on a Foxy-Jr fraction collec- tor and the system was controlled by a HP pentium PC with HP chemstation software. Samples were dried on a centrifugal evaporator and resuspended in water or Tris buffer prior to mass spectroscopy or radioimmunoassay, respectively. MATERIAL AND METHODS Materials Recombinant and purified native human TGF-α were ob- ............................................................. tained from Calbiochem (Nottingham, UK). Porcine pepsin Abbreviations: HPLC, high pressure liquid chromatography; AcN, was obtained from Sigma (P6887, Poole, UK) in the form of a acetonitrile; TFA, trifluoroacetic acid; EGF, epidermal growth factor; lyophilised powder. All other chemicals were obtained from EGF-R, epidermal growth factor receptor; PPI, proton pump inhibitor; RIA, Sigma unless stated otherwise radioimmunoassay; TGF-α, transforming growth factor α. www.gutjnl.com 788 Marchbank, Boulton, Hansen, et al Radioimmunoassay (RIA) for TGF-α a Dynatech Multimash automatic cell harvester and solubilised TGF-α-like immunoreactivity was measured using a commer- by incubation at 37°C for one hour in 200 µl of 1 M KOH. Cell cial RIA kit (BT-350; Biomedical Technologies Inc., Stoughton, extract (50 µl) was counted in a β counter in 1 ml of scintillant Gut: first published as 10.1136/gut.51.6.787 on 1 December 2002. Downloaded from Massachusetts, USA). Briefly, tubes were incubated for 24 hours (Optiphase Safe; LKB-Pharmacia, Bromma, Sweden). at 4°C, and bound and free TGF-α were separated using 50 µl/tube of donkey antisheep antibody and 50 µl of PEG followed Assay of biological activity of different forms of TGF-α in by mixing and centrifugation at 2000 rpm for 15 minutes at 4°C. vivo α Typical results gave a maximal binding ratio (Tmax tubes) of 0.5 The ability of TGF- to prevent gastric damage by indometh- and a non-specific binding ratio (To tubes) of 0.03. Sensitivity of acin and restraint in rats was assessed using previously the assay is 0.02 ng/tube. This radioimmunoassay does not cross validated methods.14 Under light ether anaesthesia, rats (male react with epidermal growth factor (EGF). Sprague Dawley, 225–250 g) had two subcutaneous cannula inserted into the back of the neck and were then placed in Pilot study to determine the effect of acid pepsin digestion of Bullman restraint cages. Once the animals had recovered, a TGF-á on immunoreactivity of TGF-á continuous subcutaneous infusion of saline or various doses α Six aliquots of TGF- were randomised to be incubated in and forms of TGF-α was started at 1 ml/h using a either Tris buffer (pH 7) or 0.1 M HCl, each containing pepsin multi-syringe infusion pump (Harvard Apparatus, Massachu- at 1 mg/ml, for one hour at 37°C. At the end of the incubation setts, USA). Thirty minutes later, 20 mg/kg of indomethacin period all samples were neutralised using 0.1 M NaOH. were injected subcutaneously via the second cannulae. Standard curves were then performed using all of these aliq- Animals were killed by stunning and cervical dislocation three uots on a single day. Data were analysed by fitting three hours later and their stomachs removed and inflated with 4 ml parameter logistic functions of loge concentration by least of 10% formalin. The next day the stomachs were opened and squares. These showed a small but significant decrease in the placed in fresh formalin prior to assessment. The stomachs α immunoreactivity of TGF- which had been treated with acid were randomly coded and all analyses of gastric damage were pepsin. Fifty per cent of maximal binding occurred at a assessed blind. Total ulcerated area (mm2/stomach) was α concentration of 5.2 ng/ml TGF- in Tris/pepsin standards and assessed using a dissecting microscope (×10) with the aid of a α 2.0 ng/ml TGF- in standard which had been treated with acid square grid. The stomachs were then embedded in wax and pepsin (significance of difference between 50% maximum the depth of damage assessed microscopically and given a α 15 binding values p<0.001). Concentrations of TGF- in gastric microscopic ulcer score, as previously described. Using this juice samples were determined taking into account these system, each stomach was given a score of 0 to 4, with 0=no small differences in immunoreactivity of the intact and damage, 1=one small erosion (less than 0.5 mm), 2=two digested forms. small or one large erosion (greater than 0.5 mm), 3=two or more large erosions, and 4=any area of ulceration extending Mass spectroscopy to the muscularis mucosa. Molecular weight was assessed by mass spectroscopy using the technique of matrix assisted laser desorption time of flight Ethics approval with a Finnigan LaserMAT mass spectrophotometer (San Local ethics approval was obtained for studies involving Jose, California, USA). Samples were mixed with 0.5 µlof human volunteers and subjects gave informed consent. http://gut.bmj.com/ alpha-cyano-4-hydroxycinnamic acid matrix (1% in 50% AcN, β 0.1% TFA). Standards used were oxidised insulin chain Study protocols (molecular weight 3496.9) and ubiquitin (molecular weight Study 1: stability of recombinant TGF-α in acid pepsin in 8564.9).
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • And Insulin-Like Growth Factor-I (IGF-I) in Regulating Human Erythropoiesis
    Leukemia (1998) 12, 371–381 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors J Ratajczak, Q Zhang, E Pertusini, BS Wojczyk, MA Wasik and MZ Ratajczak Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA The role of insulin (INS), and insulin-like growth factor-I (IGF- has been difficult to assess. The fact that EpO alone fails to I) in the regulation of human erythropoiesis is not completely stimulate BFU-E in serum-free conditions, but does do in understood. To address this issue we employed several comp- lementary strategies including: serum free cloning of CD34؉ serum containing cultures indicates that serum contains some cells, RT-PCR, FACS analysis, and mRNA perturbation with oli- crucial growth factors necessary for the BFU-E development. godeoxynucleotides (ODN). In a serum-free culture model, both In previous studies from our laboratory, we examined the ؉ INS and IGF-I enhanced survival of CD34 cells, but neither of role of IGF-I12 and KL9,11,13 in the regulation of early human these growth factors stimulated their proliferation. The influ- erythropoiesis. Both of these growth factors are considered to ence of INS and IGF-I on erythroid colony development was be crucial for the BFU-E growth.3,6,8,14 Unexpectedly, that dependent on a combination of growth factors used for stimul- + ating BFU-E growth.
    [Show full text]
  • Growth Hormone Enhances Hepatic Epidermal Growth Factor Receptor Concentration in Mice
    Growth hormone enhances hepatic epidermal growth factor receptor concentration in mice. J O Jansson, … , W G Beamer, L A Frohman J Clin Invest. 1988;82(6):1871-1876. https://doi.org/10.1172/JCI113804. Research Article The effect of growth hormone (GH) on binding of epidermal growth factor (EGF) to liver membrane preparations was investigated in hypophysectomized mice and partially GH-deficient, genetic mutant "little" (lit/lit) mice. The EGF binding of normal male mice and testosterone-treated females was higher than in normal females. Due to diminished receptor concentration, hepatic EGF binding was decreased in male and female lit/lit mice to a level that was unaffected by gender or androgen treatment. GH replacement therapy by intermittent injections and continuous infusion restored the EGF binding of hypophysectomized mice to normal male and female levels, respectively, suggesting a role for the more pulsatile GH secretion in normal males. In lit/lit mice, however, both continuous and intermittent GH resulted in EGF binding levels comparable to those in normal females. In normal males continuous GH suppressed EGF binding. In conclusion, endogenous GH secretion induces EGF receptors in mice and this effect may be modulated by sex differences in GH secretion. Find the latest version: https://jci.me/113804/pdf Growth Hormone Enhances Hepatic Epidermal Growth Factor Receptor Concentration in Mice John-Olov Jansson,** Staffan Ekberg,t Steven B. Hoath,* Wesley G. Beamer," and Lawrence A. Frohman* Divisions of*Endocrinology and ONeonatology, University of Cincinnati College ofMedicine, Cincinnati, Ohio 45267; "Jackson Laboratory, Bar Harbor, Maine 04609; and tDepartment ofPhysiology, University ofGoteborg, Sweden Abstract (IGF-I), which may function in a paracrine and autocrine as well as endocrine manner (6-8).
    [Show full text]
  • The Endometrial Lymphatic Vasculature: Function and Dysfunction
    The Endometrial Lymphatic Vasculature: Function and Dysfunction Jane E. Girling and Peter A.W. Rogers Gynaecology Research Centre, Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Victoria 3052, Australia. Corresponding Author: Dr Jane E Girling Gynaecology Research Centre Department of Obstetrics and Gynaecology The University of Melbourne The Royal Women’s Hospital Cnr Flemington Rd and Grattan St Parkville, VIC 3058, Australia Email: [email protected] Telephone: +61 3 8345 3721 Fax: +61 3 8345 3702 1 Abstract The endometrium has a complex and dynamic blood and lymphatic vasculature which undergoes regular cycles of growth and breakdown. While we now have a detailed picture of the endometrial blood vasculature, our understanding of the lymphatic vasculature in the endometrium is limited. Recent studies have illustrated that the endometrium contains a population of lymphatic vessels with restricted distribution in the functional layer relative to the basal layer. The mechanisms responsible for this restricted distribution and the consequences for endometrial function are not known. This review will summarise our current understanding of endometrial lymphatics, including the mechanisms regulating their growth and function. The potential contribution of lymphatic vessels and lymphangiogenic growth factors to various endometrial disorders will be discussed. Keywords: Blood Vessels, Decidua, Endometrium, Lymphatics, Menstruation, VEGFC, VEGFD 2 1. Introduction The endometrium has a complex and dynamic blood and lymphatic vasculature which undergoes regular cycles of growth and breakdown. These cyclic changes reflect variations in circulating sex steroids and uterine blood flow and result in cyclic patterns in tissue oxygenation, haemostasis, nutrient supply, fluid balance and leukocyte distribution. Appropriate growth and functioning of the vasculature is essential for normal endometrial function, including preparation for potential embryo implantation and subsequent pregnancy.
    [Show full text]
  • Factor-The Controlling Growth Factor-At a Sufficiently Low Value, While the Cell Population Has Ceased to Grow and Is in a Sort
    708 GENETICS: NO VICK A ND SZILARD PROC. N. A. S. EXPERIMENTS WITH THE CHEMOSTAT ON SPONTANEOUS MUTATIONS OF BACTERIA By AARON NOVICK AND LEO SZILARD INSTITUTRE OF RADIOBIOLOGY AND BIOPHYSICS, UNIVERSITY OF CHICAGO Communicated by H. J. Muller, October 18, 1950 Introduction.-All bacteria require for growth the presence of certain inorganic chemical components in the nutrient, such as potassium, phos- phorus, sulphur, etc., and with a few exceptions all bacteria require an energy-yielding carbon source, such as, for instance, glucose or lactate, etc. In addition to these elements or simple compounds, certain bacteria require more complex compounds, for instance an amino acid, which they are not capable of synthesizing. For the purposes of this presentation, any of the chemical compounds which a given strain of bacteria requires for its growth will be called a "growth factor." In general, the growth rate of a bacterial strain may be within very wide limits independent of the concentration of a given growth factor; but since at zero concentration the growth rate is zero, there must of necessity exist, at sufficiently low concentrations of the growth factor, a region in which the growth rate falls with falling concentration of the growth factor. It therefore should be possible to maintain a bacterial population over an indefinite period of time growing at a rate considerably lower than normal simply by maintaining the concentration of one growth factor-the controlling growth factor-at a sufficiently low value, while the concentrations of all other growth factors may at the same time be main- tained at high values.
    [Show full text]
  • Involvement of Vascular Endothelial Growth Factor Signaling in CLR/RAMP1 and CLR/RAMP2-Mediated Pro-Angiogenic Effect of Interme
    289-294.qxd 18/6/2010 08:32 Ì ™ÂÏ›‰·289 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 26: 289-294, 2010 289 Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells GIOVANNA ALBERTIN, ELISA SORATO, BARBARA OSELLADORE, ALESSANDRA MASCARIN, CINZIA TORTORELLA and DIEGO GUIDOLIN Department of Human Anatomy and Physiology, Section of Anatomy, University of Padova-Medical School, I-35121 Padova, Italy Received January 27, 2010; Accepted March 30, 2010 DOI: 10.3892/ijmm_00000464 Abstract. Intermedin (IMD) is a recently discovered peptide initiation and propagation by transactivating the VEGF closely related to adrenomedullin. Its principal physiological receptor-2 machinery. activity is its role in the regulation of the cardiovascular system, where it exerts a potent hypotensive effect. In addition, Introduction data were recently provided showing that this peptide is able to exert a clearcut pro-angiogenic effect both in vitro and In early 2004, a novel member of the calcitonin (CT)/calcitonin- in vivo. IMD acts through the non-selective interaction with gene related peptide (CGRP) family was independently receptor complexes formed by the dimerization of calcitonin- identified by two separate groups. Roh and colleagues (1) like receptor (CLR) with the receptor activity-modifying discovered the human form of this peptide in cells within the proteins RAMP1, 2 or 3. Thus, in the present study, the role of intermediate lobe of the pituitary and called it intermedin (IMD). CLR/RAMP complexes in mediating the pro-angiogenic effect At the same time, Takei et al (2) identified in mammals a 146- induced by IMD on human umbilical vein endothelial cells 150 amino acid prepro-hormone which yielded to a 47-amino (HUVECs) cultured on Matrigel was examined.
    [Show full text]
  • Updated November 2019 KIT Mutation the KIT Gene Is Associated With
    Updated November 2019 KIT Mutation The KIT gene is associated with autosomal dominant piebaldism, gastrointestinal stromal tumors (GISTs), and familial mastocytosis.1-3 The type of mutation identified in the KIT gene determines the symptoms/cancer risks that the individual may have. Pathogenic loss-of-function (LOF) mutations in the KIT gene are generally only associated with Piebaldism. However, pathogenic gain of function mutations in the KIT gene are associated with systemic mastocytosis and gastrointestinal stromal tumors.4,5 Piebaldism: This is a rare condition characterized by the patchy absence of melanocytes in certain areas of the skin and hair. Melanocytes produce the pigment melanin, which contributes to hair, eye, and skin color. The absence of melanocytes leads to patches of skin and hair that are lighter than normal. These unpigmented areas are typically present at birth and do not increase in size or number.6-8 Gastrointestinal stromal tumors (GIST): GISTs are tumors that occur in the gastrointestinal tract, most commonly in the stomach or small intestine. Small tumors may cause no signs or symptoms. However, some people with GISTs may experience pain or swelling in the abdomen, nausea, vomiting, loss of appetite, or weight loss. These tumors can be cancerous (malignant) or noncancerous (benign). Mastocytosis: This is a blood disorder that occurs when white blood cells called mast cells accumulate in one or more tissues (most commonly in the bone marrow). Mast cells normally trigger inflammation during an allergic reaction. When an environmental trigger activates mast cells, they release proteins that signal an immune response. In systemic mastocytosis, excess mast cells mean more proteins are being released in the tissues where the cells accumulate, leading to an increased immune response.
    [Show full text]
  • B-Cell Growth Factor
    Proc. Natl Acad. Sci. USA Vol. 79, pp. 7455-7459, December 1982 Immunology B-cell growth factor: Distinction from T-cell growth factor and B-cell maturation factor (B lymphocytes/T-cell hybridomas) TOMAS LEANDERSON*, ERIK LUNDGRENt, ERIK RUUTH*, HAKAN BORGt, HAKAN PERSSONt, AND ANTONIO COUTINHOt tLaboratory for Cell and Tissue Culture Research, *Institute of Pathology, and +Department of Immunology, UmeA University, S-901 87 UmeA, Sweden Communicated by Niels K. Jerne, July 12, 1982 ABSTRACT A T-cell hybridoma was derived by somatic cell We have initiated these studies by systematically screening hybridization between concanavalin A-activated BALB/c spleen hybridoma activities in different assays that measure either cells and the AKR thymoma BW 5147. Media conditioned by hy- growth or maturation ofall B lymphocytes, regardless ofclonal bridoma cells, even at high dilutions (1:1,000) support the growth specificity. We chose to study activated rather than resting B oflipopolysaccharide-stimulated B-cell blasts but not that ofT-cell cells because of the-overwhelming evidence that initiation of growth factor (TCGF)-reactive T-cells. This activity, herein des- cooperative B-cell responses requires direct cellular interaction ignated B-cell growth factor (BCGF), has a Mr of =20,000 and it (13, 14). In this report we describe a hybridoma clone secreting can readily be separated from TCGF (Mr "30,000) by gel filtra- a factor that supports growth but not maturation of lipopoly- tion. BCGF is constitutively produced by the hybridoma cells, it saccharide (LPS)-activated B-cell blasts and is devoid of is removed from conditioned media by incubation with target cells T-cell at +4°C, and it is equally effective on B-cell blasts carrying dif- growthfactor(TCGF) andT-cellreplacingfactor(TRF) activities.
    [Show full text]
  • Erythropoietin Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Erythropoietin Using ALZET Osmotic Pumps Q8440: S. Dey, et al. Sex-specific brain erythropoietin regulation of mouse metabolism and hypothalamic inflammation. JCI Insight 2020;5(5): Agents: Erythropoietin, recombinant human Vehicle: Saline; Route: CSF/CNS (intracerebral); IV; Species: Mice; Pump: 2006; Duration: 14 days; ALZET Comments: Dose (3000 U/kg); Controls received mp w/ vehicle; animal info (Tg21 mice); recombinant human Erythropoietin aka recombinant human EPO; ALZET brain infusion kit 3 used; Brain coordinates (midline, 1.00 mm; antero- posterior, 0.34 mm; dorsoventral, 2.30 mm); dental cement used;replacement therapy (Erythropoietin); Q8045: E. K. Kim, et al. Local Subcutaneous Injection of Erythropoietin Might Improve Fat Graft Survival, Whereas Continuous Infusion Using an Osmotic Pump Device Was Harmful by Provoking an Overwhelming Foreign Body Reaction in a Nude Mouse Model. Archives of Aesthetic Plastic Surgery 2018;24(3):128-133 Agents: Erythropoietin Vehicle: Saline; Route: SC; Species: Mice; Pump: 1007D; Duration: 1 week; ALZET Comments: Dose (1,000 IU of EPO); animal info (36 weeks old, CD-1, Male, 20-25 g); EPO aka hemangiogenic and antiapoptotic factor ; dependence; Q4880: E. H. Sanchez-Mendoza, et al. Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions. Journal of Visualized Experiments 2016;107(1-9 ALZET Comments: Erythropoietin, recombinant human; CSF/CNS; Mice; 30 days; Controls received
    [Show full text]
  • Metabolische Signaturen Des Insulin-Like Growth Factor 1 Anhand Von Metabolom-Untersuchungen in Plasma Und Urin
    Institut für Klinische Chemie und Laboratoriumsmedizin Direktor: Univ.-Prof. Dr. med. M. Nauck Universitätsmedizin der Universität Greifswald Metabolische Signaturen des Insulin-like growth factor 1 anhand von Metabolom-Untersuchungen in Plasma und Urin Inaugural-Dissertation zur Erlangung des akademischen Grades Doktor der Medizin (Dr. med.) der Universitätsmedizin der Universität Greifswald 2019 Vorgelegt von Henrike Knacke geb. am 07.02.1992 in Eutin Name des Dekans: Prof. Dr. Max P. Baur Erstgutachter: PD Dr. Nele Friedrich Zweitgutachter: Prof. Dr. Martin Reincke (München) Tag der Disputation: 29.11.2019 um 13:00 Uhr Ort der Disputation: Klinik für Innere Medizin A, Seminarraum 7.0.15/17 Universitätsmedizin Greifswald INHALTSVERZEICHNIS 1. EINLEITUNG ......................................................................................................................................... 3 1.1 Fragestellung ..................................................................................................................................... 3 1.2 Regulierung der IGF-I-Sekretion ........................................................................................................ 3 1.3 IGF-Binding Proteins .......................................................................................................................... 4 1.4 IGF-I Signalweg und Effekte ............................................................................................................... 4 1.5 Physiologische Funktionen von IGF-I und assoziierte Erkrankungen
    [Show full text]
  • Insulin As a Growth Factor
    003 1-3998/85/1909-0879$02.00/0 PEDIATRIC RESEARCH Vol. 19, No. 9, 1985 Copyright O 1985 International Pediatric Research Foundation, Inc Printed in U.S. A. Insulin as a Growth Factor D. J. HILL AND R. D. G. MILNER Departrnenl c!j'Pucdiutricc, Unive,:sitj. of Sl~effield,Cliildren :s Hospital, Shefic~ld,England ABSTRACT. Insulin is a potent mitogen for many cell attention than its well known, acute metabolic actions. Insulin types in vitro. During tissue culture, supraphysiological also can influence growth in vivo. The poor growth of a chilld concentrations of insulin are necessary to promote cell with diabetes (1) contrasts with the overgrowth of the hyperin- replication in connective or musculoskeletal tissues. Insulin sulinemic infant of a diabetic mother (2). The growth-promoting promotes the growth of these cells by binding, with low effect of insulin in vivo was demonstrated experimentally by affinity, to the type I insulin-like growth factor (IGF) Salter and Best in 1953 (3); these investigators restored growth receptor, not through the high affinity insulin receptor. In to hypophysectomized rats by treatment with insulin and a high other cell types, such as hepatocytes, embryonal carcinoma carbohydrate diet. Rats given insulin grew as well as those given cells, or mammary tumor cells, the type I IGF receptor is growth hormone but consumed substantially more food. Any virtually absent, and insulin stimulates the growth of these analysis of the action of insulin in promoting growth must clearly cells at physiological concentrations by binding to the high separate those effects which are due to anabolism resulting frc~m affinity insulin receptor.
    [Show full text]
  • Early Decrease in Serum Amphiregulin Or Vascular Endothelial Growth Factor Levels Predicts Sorafenib Efficacy in Hepatocellular Carcinoma
    ONCOLOGY REPORTS 41: 2041-2050, 2019 Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma CORINNE GODIN1,2*, SANDRA BODEAU2,3*, ZUZANA SAIDAK1,4, CHRISTOPHE LOUANDRE2, CATHERINE FRANÇOIS5, JEAN-CLAUDE BARBARE6, ROMAIN CORIAT7,8, ANTOINE GALMICHE1,2 and CHLOÉ SAUZAY1,2 1Equipe CHIMERE, EA 7516, Université de Picardie Jules Verne; 2Laboratoire de Biochimie; 3Laboratoire de Pharmacologie; 4Service d'Oncobiologie Moléculaire, Centre de Biologie Humaine, CHU Sud; 5EA4294, Université de Picardie Jules Verne; 6Délégation à la Recherche Clinique et à l'Innovation, CHU Sud, 80054 Amiens; 7Gastroenterology and Digestive Oncology Unit, Cochin University Hospital, APHP; 8Unité Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France Received June 29, 2018; Accepted November 15, 2018 DOI: 10.3892/or.2018.6922 Abstract. Sorafenib is the standard of care for the treatment at the transcriptional and post-transcriptional levels. All HCC of advanced hepatocellular carcinoma (HCC). However, patients in our cohort had detectable concentrations of AREG identifying secreted biomarkers that predict sorafenib efficacy and VEGF both at baseline and after sorafenib treatment. The in all HCC patients remains challenging. It was recently decreased serum levels of AREG and VEGF after 15 days of reported that sorafenib interferes with protein homeostasis sorafenib treatment were significantly associated with better and inhibits global translation in tumour cells. A likely overall and progression-free survival. The results of the consequence of this inhibition would be the interruption multivariate analysis demonstrated that a decrease in AREG of autocrine loops. The aim of the present study was to was an independent prognostic indicator of overall survival investigate the effect of sorafenib on two growth factors (hazard ratio, 0.208; 95% confidence interval, 0.173‑0.673; implicated in autocrine loops and HCC tumour invasion: P=0.0003).
    [Show full text]